Antiplatelet agents for prevention of pre-eclampsia and its consequences: a systematic review and individual patient data meta-analysis.

ABSTRACT: BACKGROUND: There is now good evidence that antiplatelet agents (principally low dose aspirin) prevent pre-eclampsia, a leading cause of morbidity and mortality for pregnant women and their babies. A Cochrane Review identified moderate, but clinically important, reductions in the relative risks of pre-eclampsia (19%), preterm birth (7%) and perinatal mortality (16%) in women allocated antiplatelets, rather than placebo or no antiplatelet.Uncertainty remains, however, about whether some women (in terms of risk) benefit more than others, what dose of aspirin is best and when in pregnancy treatment should ideally start. Rather than undertake new trials, the best way to answer these questions is to utilise existing individual patient data from women enrolled in each trial. METHODS/DESIGN: Syst

SUBMITTER: The Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Steering Group on behalf of the PARIS Collaboration 

PROVIDER: S-EPMC555958 | biostudies-literature | 2005 Mar

REPOSITORIES: biostudies-literature